Sulzer's INRange aims to cut heart valve complications
This article was originally published in Clinica
Executive Summary
Sulzer Medica's cardiac surgery subsidiary, Sulzer Carbomedics, has begun clinical trials of INRange, a monitored heart valve service that measures the effects on patients of the anticoagulant drugs they take. The trials are designed to demonstrate that mechanical heart valve patients taking oral anticoagulants can reduce the complications associated with warfarin therapy by staying within the prescribed therapeutic range with the help of self-testing and telephone monitoring.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.